Pharmaceutical company uniQure announced new executive appointments to its leadership team and nominations to its board of directors, including the promotion of Christian Klemt from global controller to chief accounting officer. These actions further uniQure's expansion in the United States and add additional expertise in gene therapy research, development, operations, manufacturing and commercial readiness, the company stated.
Since joining uniQure in 2015, Klempt has transformed the finance and accounting functions at uniQure, dramatically improved the internal control environment, and enhanced the financial planning and analysis functions. He also oversaw the company's transition to a domestic U.S. filer and conversion to U.S. Generally Accepted Accounting Principles.
The company further announced the nominations of Madhavan Balachandran and Jeremy Springhorn to its board of directors. An Extraordinary General Meeting of Shareholders (EGM) will be held on Sept. 14 for purposes of considering their elections to the board.
Balachandran is a pharmaceutical industry executive and has more than 40 years of experience in manufacturing and operations. He was previously with Amgen, where he served as executive vice president of operations, overseeing global operations and reporting directly to the CEO. Balachandran held similar positions at Copley Pharmaceuticals and Burroughs Wellcome.
Springhorn is an industry veteran with 25 years of experience in leading scientific, business development, and corporate strategy organizations. He currently serves as partner of corporate development with Flagship Pioneering and was previously at Alexion Pharmaceuticals as vice president, corporate development.